enzastaurin has been researched along with folic acid in 1 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (folic acid) | Trials (folic acid) | Recent Studies (post-2010) (folic acid) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 30,001 | 1,945 | 10,195 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barata, F; Barlesi, F; Bearz, A; Bepler, G; Chiappori, A; Chouaki, N; Iscoe, N; Liepa, AM; Park, K; Reck, M; Scagliotti, G; Soria, JC; von Pawel, J; Wagle, A; Zhao, YD | 1 |
1 trial(s) available for enzastaurin and folic acid
| Article | Year |
|---|---|
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Female; Folic Acid; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Salvage Therapy; Survival Rate; Vitamin B 12 | 2010 |